Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 16, 2016 02:30 ET | Source: Wilson Therapeutics AB

Wilson Therapeutics appoints Rick Lilley as Chief Regulatory Officer

Wilson Therapeutics AB (publ), announces the appointment of Rick Lilley as Chief Regulatory Officer. Dr Lilley will report to CEO Jonas Hansson and will join the company’s management team. Dr Lilley...
June 16, 2016 02:30 ET | Source: Wilson Therapeutics AB

Wilson Therapeutics utser Rick Lilley till Chief Regulatory Officer

Wilson Therapeutics AB (publ), tillkännager att Rick Lilley har rekryterats som Chief Regulatory Officer. Han kommer att rapportera till VD Jonas Hansson och ingå i bolagets ledningsgrupp. Dr Rick...
June 16, 2016 02:00 ET | Source: Wilson Therapeutics AB

Wilson Therapeutics utser Erik Penser till likviditetsgarant

Wilson Therapeutics AB (publ) har utsett Erik Penser Bankaktiebolag till likviditetsgarant för bolagets aktie, som är noterad i Mid Cap-segmentet på Nasdaq Stockholm. Kortfattat innebär åtagandet att...
June 16, 2016 02:00 ET | Source: Wilson Therapeutics AB

Wilson Therapeutics appoints Erik Penser as liquidity provider

Wilson Therapeutics AB (publ) has appointed Erik Penser Bankaktiebolag as liquidity provider for the company’s share which is listed in the Mid Cap segment on Nasdaq Stockholm. This undertaking means...
June 13, 2016 02:00 ET | Source: Wilson Therapeutics AB

Utilization of the over-allotment option in Wilson Therapeutics and notice of stabilization

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA ABG Sundal Collier, Carnegie Investment Bank and DNB Markets...
June 13, 2016 02:00 ET | Source: Wilson Therapeutics AB

Utnyttjande av övertilldelningsoptionen i Wilson Therapeutics samt meddelande om stabiliseringsåtgärder

EJ FÖR PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, I ELLER TILL USA, KANADA, JAPAN ELLER AUSTRALIEN ABG Sundal Collier, Carnegie Investment Bank och DNB Markets (”Joint...
May 31, 2016 02:00 ET | Source: Wilson Therapeutics AB

Förändring av antalet aktier i Wilson Therapeutics

Antalet aktier och röster i Wilson Therapeutics AB (publ) har förändrats som ett resultat av den nyemission som genomfördes i samband med noteringen av bolagets aktier på Nasdaq Stockholm. Idag, den...
May 31, 2016 02:00 ET | Source: Wilson Therapeutics AB

Change in number of shares in Wilson Therapeutics

The number of shares and votes in Wilson Therapeutics AB (publ) has changed as a result of the new issue of shares that was made in connection with the listing of the company’s shares on Nasdaq...
May 30, 2016 02:00 ET | Source: Wilson Therapeutics AB

Wilson Therapeutics presents encouraging clinical data on Decuprate® at the Congress of the European Academy of Neurology

Wilson Therapeutics AB (publ), announces that preliminary data from the company’s ongoing Phase II clinical trial for Decuprate® (bis-choline tetrathiomolybdate; WTX101) in Wilson Disease were...
May 30, 2016 02:00 ET | Source: Wilson Therapeutics AB

Wilson Therapeutics presenterar lovande data för Decuprate® på The Congress of the European Academy of Neurology

Wilson Therapeutics AB (publ), tillkännager att preliminära data från bolagets pågående kliniska fas II-studie av Decuprate® (biskolintetrathiomolybdat; WTX101) som behandling för Wilsons sjukdom...